Table 4.
General characteristics of patients with pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2 (PIMS-TS), details on organ dysfunction and applied therapies.
| Characteristic | n (%) | Median (IQR) |
|---|---|---|
| General characteristics | ||
| Age in years | 11 (9–11.5) | |
| Gender | ||
| Female | 2 (22%) | |
| Male | 7 (78%) | |
| Body mass index in kg/m2 | 20 (16.8–26.4) | |
| Organ dysfunction | ||
| Acute respiratory distress syndrome | 2 (22%) | |
| Shock | 8 (89%) | |
| Myocardial injury | 4 (44%) | |
| Renal dysfunction | 6 (67%) | |
| Hepatic dysfunction | 4 (44%) | |
| Coagulation disturbances | 6 (67%) | |
| Supportive measures | ||
| Any type of respiratory support | 9 (100%) | |
| Highest level of respiratory support | ||
| Invasive ventilation | 5 (56%) | |
| Non-invasive ventilation (NIV) | 1 (11%) | |
| Continuous positive airway pressure (CPAP) | 0 (0%) | |
| High-flow nasal cannula (HFNC) | 1 (11%) | |
| Low-flow nasal cannula (LFNC) | 2 (22%) | |
| Duration of respiratory support per patient in days | ||
| Invasive ventilation (n = 5) | 3.8 (3–8) | |
| NIV (n = 3) | 1 (0.4–4) | |
| CPAP (n = 0) | 0 | |
| HFNC (n = 2) | 3 (2–4) | |
| LFNC (n = 3) | 1 (1–6.3) | |
| Vasopressors or inotropes | 8 (89%) | |
| Duration in days | 3.5 (3-4.8) | |
| Extracorporeal membrane oxygenation (ECMO) | 0 | |
| Continuous renal replacement therapy | 1 (11%) | |
| Duration in days | 3 | |
| Cytokine absorption therapy | 1 (11%) | |
| Drug therapies | ||
| Hydroxychloroquine | 3 (33%) | |
| Intravenous immunoglobulin (IVIG) | 6 (67%) | |
| Steroids | 6 (67%) | |
| Biological agents | 6 (67%) | |
| Anakinra | 6 (67%) | |
| Tocilizumab | 2 (22%) | |
| Combinations of immunotherapies | ||
| None | 1 (11%) | |
| IVIG only | 1 (11%) | |
| Anakinra only | 1 (11%) | |
| Steroids and anakinra | 1 (11%) | |
| Steroids and IVIG | 1 (11%) | |
| IVIG, steroids, and anakinra | 2 (22%) | |
| IVIG, steroids, anakinra, and tocilizumab | 2 (22%) | |
| Outcome | ||
| Patients alive on discharge | 9 (100%) |
IVIG, intravenous immunoglobulins.